Home GPCR & G Protein CCR

CCR Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S8512 Cenicriviroc Cenicriviroc is a potent, orally active dual inhibitor of CC chemokine receptor 2 (CCR2) and CCR5. This compound also inhibits HIV-1 and HIV-2 with potent anti-inflammatory and antiinfective activity.
Nature, 2025, 10.1038/s41586-024-08535-1
International Journal of Biological Sciences, 2023 May 8, 2572-2587
Int J Biol Sci, 2023, 19(8):2572-2587
S2004 Vicriviroc Malate Vicriviroc is a potent CCR5 antagonist with IC50 of 0.91 nM, showing broad-spectrum activity against genetically diverse HIV-1 isolates, and also drug-resistant viruses with RTI, PRI, or MDR phenotypes. Phase 3.
Nature, 2013, 493(7430):51-5
Cancer Res, 2012, 72(15):3839-50
J Antimicrob Chemot, 2011, 66(4):802-12
Verified customer review of Vicriviroc Malate
S3479 R243 R243 is an inhibitor of Chemokine (C-C motif) receptor 8 (CCR8) signaling and chemotaxis.
Cell Proliferation, 2025, e70032
Cell Prolif, 2025, e70032.
Journal of Experimental Medicine, 2019, 2763–2777
E6879New Carboxyethylgermanium sesquioxide Carboxyethylgermanium sesquioxide（Repagermanium, DMX-200) is an orally active small‑molecule inhibitor of the C‑C chemokine receptor type 2 (CCR2) pathway and is used in combination with an angiotensin receptor blocker (ARB) to reduce proteinuria and slow kidney function decline in proteinuric chronic kidney diseases such as focal segmental glomerulosclerosis (FSGS).
E1584New CCR6 inhibitor 1 CCR6 inhibitor-1 is a potent and selective inhibitor of CCR6 with IC50 of 0.45 nM and 6 nM for monkey and human CCR6, respectively. It potently inhibits human B-cell migration and ERK phosphorylation, exhibiting potential as a treatment for autoimmune diseases.
S2907 Pirfenidone Pirfenidone is an inhibitor for TGF-β production and TGF-β stimulated collagen production, reduces production of TNF-α and IL-1β, and also has anti-fibrotic and anti-inflammatory properties. Pirfenidone attenuates chemokine (CC motif) ligand-2 (CCL2) and CCL12 production with anti-fibrotic activity. Phase 3.
Cell, 2026, S0092-8674(26)00223-0
Redox Biol, 2026, 93:104164
PLoS One, 2026, 21(4):e0342991
Verified customer review of Pirfenidone
S3032 Bindarit (AF 2838) Bindarit exhibits selective inhibition against monocyte chemotactic proteins MCP-1/CCL2, MCP-3/CCL7 and MCP-2/CCL8.
International Journal of Biological Sciences, 2025, 21(14):6113-6131
Exp Mol Med, 2024, 56(2):408-421.
PLoS Pathog, 2024, 20(11):e1012747
Verified customer review of Bindarit (AF 2838)
S0777 Isuzinaxib (APX-115 free base) Isuzinaxib (APX-115 free base, Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. This compound significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.
Insects, 2026, 17(3)300
American Journal of Physiology-Renal Physiology, 2024, F202-F218
S3205 Perillaldehyde Perillaldehyde (Perilladehyde, Perillal, PAE, PA), the main component of Perilla frutescens (a traditional medicinal antioxidant herb), inhibits BaP-induced AHR activation and ROS production, inhibits BaP/AHR-mediated release of the CCL2 chemokine, and activats the NRF2/HO1 antioxidant pathway.
Front Cell Dev Biol, 2025, 13:1598520